BABA vs BIRD

The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.

The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 1/9, indicating severe operational and profitability concerns. Despite a low Price/Book of 0.65 and Price/Sales of 0.21 suggesting potential value, the company is deeply unprofitable with negative margins across all key metrics, including a -51.90% profit margin and -93.02% ROE. Revenue is contracting at -23.30% YoY, and insider selling activity over the past six months signals management's lack of confidence. While analysts have a bullish target price of $14.00, the single analyst coverage, deteriorating fundamentals, and absence of Altman Z-Score due to likely negative retained earnings or equity raise serious distress risks.